Context Based on observational and interventional data for middle-aged cohorts
(aged 40-64 years), serum cholesterol level is known to be an established
major risk factor for coronary heart disease (CHD). However, findings for
younger people are limited, and the value of detecting and treating hypercholesterolemia
in younger adults is debated.
Objective To evaluate the long-term impact of unfavorable serum cholesterol levels
on risk of death from CHD, cardiovascular disease (CVD), and all causes.
Design, Setting, and Participants Three prospective studies, from which were selected 3 cohorts of younger
men with baseline serum cholesterol level measurements and no history of diabetes
mellitus or myocardial infarction. A total of 11,017 men aged 18 through 39
years screened in 1967-1973 for the Chicago Heart Association Detection Project
in Industry (CHA); 1266 men aged 25 through 39 years examined in 1959-1963
in the Peoples Gas Company Study (PG); and 69,205 men aged 35 through 39 years
screened in 1973-1975 for the Multiple Risk Factor Intervention Trial (MRFIT).
Main Outcome Measures Cause-specific mortality during 25 (CHA), 34 (PG), and 16 (MRFIT) years
of follow-up; mortality risks; and estimated life expectancy in relation to
baseline serum cholesterol levels.
Results Death due to CHD accounted for 26%, 34%, and 28% of all deaths in the
CHA, PG, and MRFIT cohorts, respectively; and CVD death for 34%, 42%, and
39% of deaths in the same cohorts, respectively. Men in all 3 cohorts with
unfavorable serum cholesterol levels (200-239 mg/dL [5.17-6.18 mmol/L] and ≥240
mg/dL [≥6.21 mmol/L]) had strong gradients of relative mortality risk.
For men with serum cholesterol levels of 240 mg/dL or greater (≥6.21 mmol/L)
vs favorable levels (<200 mg/dL [<5.17 mmol/L]), CHD mortality risk
was 2.15 to 3.63 times greater; CVD disease mortality risk was 2.10 to 2.87
times greater; and all-cause mortality was 1.31 to1.49 times greater. Hypercholesterolemic
men had age-adjusted absolute risk of CHD death of 59 per 1000 men in 25 years
(CHA cohort), 90 per 1000 men in 34 years (PG cohort), and 15 per 1000 men
in 16 years (MRFIT cohort). Absolute excess risk was 43.6 per 1000 men (CHA),
81.4 per 1000 men (PG), and 12.1 per 1000 men (MRFIT). Men with favorable
baseline serum cholesterol levels had an estimated greater life expectancy
of 3.8 to 8.7 years.
Conclusions These results demonstrate a continuous, graded relationship of serum
cholesterol level to long-term risk of CHD, CVD, and all-cause mortality,
substantial absolute risk and absolute excess risk of CHD and CVD death for
younger men with elevated serum cholesterol levels, and longer estimated life
expectancy for younger men with favorable serum cholesterol levels.
For middle-aged populations, especially men, serum cholesterol consistently
has been shown to be a significant risk factor for coronary heart disease
(CHD) and the major cardiovascular diseases (CVDs).1-5
The relationship is continuous, graded, strong, independent of other risk
factors, predictive, and generally assessed as etiologically significant.
This judgment is reinforced by results of many randomized controlled trials
in middle-aged and older persons with average, borderline high, and high serum
cholesterol levels; these trials demonstrate that effective, sustained reduction
of serum cholesterol levels by dietary measures, pharmacologic means, or both
reduces CHD and CVD risk.4,5
In contrast, for younger adults, the only available long-term prospective
data on this relationship are for 3 cohorts of limited size: Johns Hopkins
male medical students and men and women aged 31 to 39 years at baseline in
the Framingham study.6,7 Possibly
reflecting this situation, there has been debate on the merits of population-wide
measurement of serum cholesterol levels in younger adults to identify and
treat those at higher CHD and CVD risk.8-14
This article adds extensive information on serum cholesterol levels
and risk of CHD and CVD in younger men. For 3 large cohorts of younger men
from the Chicago Heart Association Detection Project in Industry (CHA), Chicago
Peoples Gas Company (PG), and Multiple Risk Factor Intervention Trial (MRFIT)
studies, we provide data on the relationship of serum cholesterol to long-term
mortality from CHD, CVD, and all causes.
This report focuses on 3 cohorts of younger men from 3 long-term prospective
epidemiologic studies. Baseline methods and follow-up procedures have been
described.3,5,15
A summary of these is provided herein.
Men in the CHA cohort were aged 18 through 39 years at baseline. From
late 1967 to early 1973, the CHA study surveyed 39,572 men and women at 84
cooperating Chicago companies and organizations. All employees were invited
to participate; the response rate was 55%. Two trained and standardized 4-person
field teams collected demographic information, medical history, and medical
treatment data; information on smoking status; measurement of height, weight,
heart rate, and a single supine blood pressure; resting electrocardiogram
(ECG); and performed venipuncture for blood chemistry measurements. Serum
cholesterol level was determined by the Levine and Zak method.16
Criteria of the Pooling Project3 and the Hypertension
Detection and Follow-up Program17 were used
to code ECG abnormalities. The cohort in this study is 11,017 men aged 18
through 39 years at baseline, with no history of diabetes mellitus or myocardial
infarction (MI).
Methods of follow-up (mean, 25 years) to ascertain vital status include
local procedures (eg, inquiry to employers and telephone and letter communications
with participants) and use of Social Security Administration and National
Death Index records. Vital status is known for more than 99% of the cohort.
Men in the PG cohort were aged 25 through 39 years at baseline. On January
2, 1959, 1609 men aged 25 through 39 years were employed by the Peoples Gas
Company. Of these, 1411 (87.7%) underwent standardized examination (December
1959–December 1963) in the PG medical department. The cohort for this
study comprises 1266 men who were free of clinical diabetes mellitus and CHD
and had complete baseline data. The standardized baseline survey included
medical history, physical examination, 3 blood pressure measurements averaged
for analyses, and serum cholesterol levels measured using the method described
by Abell et al.18
Long-term follow-up of the PG cohort (mean, 34 years) was done through
the PG medical department, which is a recipient of mortality information in
relation to employee benefits. Verification included checks with the National
Death Index since its inception in 1979. Vital status of every man in the
PG cohort is known.
Men in the MRFIT cohort were aged 35 through 39 years at baseline. Altogether,
361,662 men aged 35 through 57 years were screened (1973-1975) at 22 centers
in 18 US cities for recruitment for MRFIT. The focus here is on 69,205 men
aged 35 through 39 years at baseline with complete data on baseline risk factors
and who were free of diabetes mellitus and MI. To assess trial eligibility,
the first screening included measurements of blood pressure and serum cholesterol
levels; current smoking (by questionnaire), including number of cigarettes
per day; and conditions for exclusion, ie, drug treatment for diabetes mellitus
and previous hospitalization for MI. Seated blood pressure was measured according
to a standardized protocol by trained, certified staff. Three readings per
man were taken; the average of the second and third systolic blood pressure
readings was used for analyses. Serum total cholesterol level was determined
in 15 standardized local laboratories by the Lieberman-Burchard color reaction
and use of serum calibrators to yield values equivalent to Abell-Kendall reference
values.5,15,18
The men's vital status (mean follow-up, 16 years) was ascertained through
the US National Death Index and, prior to 1979, through the Social Security
Administration. Cause of death is known for 99% of decedents.
To evaluate strength of the relationship between serum cholesterol level
and CHD risk for younger vs middle-aged men, summary data are reported for
cohorts of men aged 40 through 59, 40 through 59, and 40 through 57 years
at baseline in these 3 studies (n = 8955, 1416, and 258,570 for the CHA, PG,
and MRFIT studies, respectively).
Classification of Underlying Cause of Death
For CHA and PG cohort decedents, underlying cause of death was coded
by a trained staff professional, using the International
Classification of Diseases, Eighth Revision (ICD-8). For the MRFIT
cohort, this was done by a nosologist using International
Classification of Diseases, Ninth Revision (ICD-9). Coders had access
only to death certificates; they were blinded to baseline data.
Death from all CHD was defined for CHA and PG cohorts as ICD-8 codes 410 to 414 and for the MRFIT cohort as ICD-9 codes 410 to 414 and 429.9; MI, code 410 (all cohorts); all CVD
deaths, ICD-8 codes 400 to 445.9 for the CHA and
PG cohorts and ICD-9 codes 390 to 459 for the MRFIT
cohort; all cancers, codes 140 to 209 (all cohorts); violence, for the CHA
and PG cohorts, ICD-8 codes E800 to E999 exclusive
of codes E930-E936 and for the MRFIT cohort, ICD-9
codes 800 to 999.
Mortality rates were age-adjusted (direct method) to age distribution
of all men in an age stratum. Cox multivariate proportional hazards regression
was used to calculate relative risks (RRs) and 95% confidence intervals across
baseline serum cholesterol level strata and to obtain multivariate-adjusted
coefficients for the relation of serum cholesterol level to mortality end
points.
Cox multivariate proportional hazards regression coefficients for the
relation of serum cholesterol level to all-cause mortality were used to estimate
years of greater life expectancy for men with baseline serum cholesterol levels
less than 200 mg/dL (<5.17 mmol/L) vs men with serum cholesterol levels
of at least 240 mg/dL (≥6.21 mmol/L).5,15
Thus, the coefficient for this relationship for men in the CHA cohort aged
18 through 39 years is 0.0051. Average serum cholesterol level for the 6888
men with values less than 200 mg/dL (<5.17 mmol/L) was 167.8 mg/dL (4.35
mmol/L); for the 974 men with values of at least 240 mg/dL (≥6.21 mmol/L),
it was 262.1 mg/dL (6.79 mmol/L), ie, 94.3 mg/dL (2.44 mmol/L) higher. By
exponentiation, estimated RR of death for the former vs the latter subcohort
is e−0.0051 × 94.3 = e−0.4809 = 0.618.
To estimate impact of this lower serum cholesterol level on life expectancy,
we used the Cox coefficient for the relationship of age to all causes mortality,
0.0718. The product for serum cholesterol level exponentiation, e0.0051
× 94.3 = e0.4809, is also obtained with multiplication
of the age coefficient, 0.0718, by 6.70, indicating that a serum cholesterol
level of 167.8 mg/dL (4.35 mmol/L) vs 262.1 mg/dL (6.79 mmol/L) is equivalent
to these men being, on average, 6.7 years younger, eg, age 23.0 years rather
than age 29.7 years. From US life tables,19
male life expectancy at age 29.7 years is 43.1 years and at age 23.0 years,
50.5 years; ie, 7.4 years estimated greater longevity is attributable to serum
cholesterol levels of 167.8 mg/dL (4.35 mmol/L) vs 262.1 mg/dL (6.79 mmol/L).
In the earliest baseline survey, mean serum cholesterol levels of the
PG cohort were higher than that of the other 2 cohorts, as was prevalence
of cigarette smoking (Table 1).
Results for baseline serum cholesterol levels and long-term mortality by cause
were consistent for the 3 younger adult male cohorts (Table 2, Table 3, and Table 4).
Death due to CHD accounted for 26%, 34%, and 28% of all deaths in the
CHA, PG, and MRFIT cohorts, respectively. Multivariate-adjusted risk of CHD
death was higher by 3.46 (CHA cohort), 2.15 (PG cohort), and 3.63 (MRFIT cohort)
times for each subcohort with elevated serum cholesterol levels according
to the criterion of the US National Cholesterol Education Program (≥240
mg/dL [≥6.21 mmol/L]) compared with the subcohort with desirable levels
(<200 mg/dL [<5.17 mmol/L]). Results were similar for fatal acute MI
(RRs: 3.99, 3.22, and 3.47 for the CHA, PG, and MRFIT cohorts, respectively)
and for other CHD death (CHD death excluding MI) (RRs: 2.88, 1.64, and 3.86
for the 3 cohorts, respectively) (data not shown).
Absolute risk of CHD death and absolute excess risk—the difference
in absolute risk with high baseline serum cholesterol levels vs risk with
favorable levels—were related to duration of follow-up (Table 2, Table 3, and Table 4). Thus, with serum cholesterol
levels of 240 mg/dL or higher (≥6.21 mmol/L), absolute risk was 15.5 per
1000 men in 16 years (from average age 37 to age 53 years) for the MRFIT cohort;
54.2 per 1000 men in 25 years (from age 30 to age 55 years) for the CHA cohort;
and 154.0 per 1000 men in 34 years (from age 32 to age 66 years) for the PG
cohort. Absolute excess risk for these subcohorts, compared with those with
serum cholesterol levels less than 200 mg/dL (<5.17 mmol/L), was 12.1 per
1000 men (MRFIT), 43.6 per 1000 men (CHA), and 81.4 per 1000 men (PG).
Relative risks were particularly large for subcohorts with severe hypercholesterolemia
(≥280 mg/dL [≥7.24 mmol/L]) vs those with low serum cholesterol levels
(<160 mg/dL [<4.14 mmol/L]); for all CHD deaths, the RRs were 11.93,
8.06, and 8.09 for the CHA, PG, and MRFIT cohorts, respectively (Table 2, Table 3, and Table 4).
The relation of serum cholesterol levels to risk was continuous and graded
across the entire distribution; rates were lowest with serum cholesterol levels
lower than 160 mg/dL (<4.14 mmol/L).
For all CHD death, Cox multivariate-adjusted coefficients for the relation
of baseline serum cholesterol level to risk were 0.0147, 0.0088, and 0.0099
for the CHA, PG, and MRFIT cohorts, respectively (Table 2, Table 3, and Table 4), yielding RRs of 1.80, 1.42, and
1.49 for the CHA, PG, and MRFIT cohorts, respectively, for serum cholesterol
levels higher by 40 mg/dL (1.03 mmol/L). These are much higher RRs than for
the cohorts of middle-aged men (aged 40-59, 40-59, and 40-57 years) in these
studies—1.20, 1.10, and 1.29 for the CHA, PG, and MRFIT cohorts, respectively
(Cox multivariate coefficients, 0.0046, 0.0023, and 0.0064, respectively).
Results were similar for other CHD mortality end points.
Because the CHA and PG cohorts had longer follow-up (25 and 34 years,
respectively), analyses were done for 2 periods to assess whether the strong
serum cholesterol level–CHD death relationship prevailed during both
earlier and later years of follow-up. For the CHA cohort, during the first
15 years of follow-up, multivariate Cox coefficients for this relationship
were 0.0183 (t = 6.508; 57 CHD deaths) and for the
next 10 years, 0.0130 (t = 6.293; 146 CHD deaths)
(RRs, 2.08 and 1.68 for serum cholesterol levels higher by 40 mg/dL (1.03
mmol/L); the difference between these coefficients is not significant (t = −1.528). For the PG cohort, Cox coefficients
for the first 23 years of follow-up were 0.0109 (t
= 3.241; 49 CHD deaths) and for the next 11 years, 0.0072 (t = 2.325; 66 CHD deaths) (RRs, 1.55 and 1.33, respectively); the difference
between these 2 coefficients is not significant (t
= −0.430).
Death due to CVD accounted for 34%, 42%, and 39% of all deaths in the
CHA, PG, and MRFIT cohorts, respectively. Results for the relationship of
serum cholesterol level to risk of CVD death were similar to those for CHD
deaths (Table 2, Table 3, and Table 4),
with RRs of 2.18, 2.10, and 2.87 for the CHA, PG, and MRFIT cohorts, respectively,
for serum cholesterol levels of at least 240 mg/dL (≥6.21 mmol/L).
All-Cause Mortality and Longevity
For all 3 cohorts, baseline serum cholesterol level was significantly
related to risk of mortality from all causes (Table 2, Table 3, and Table 4). The relationship was generally
continuous, graded, strong, and independent of other risk factors. With serum
cholesterol level higher by 40 mg/dL (1.03 mmol/L), multivariate-adjusted
Cox coefficients (0.0051, 0.0029, and 0.0043) yielded RR estimates of 1.23,
1.12, and 1.19 for the CHA, PG, and MRFIT cohorts, respectively.
For men with favorable baseline serum cholesterol levels (<200 mg/dL
[<5.17 mmol/L]) vs men with hypercholesterolemia (≥240 mg/dL [≥6.21
mmol/L]), baseline average serum cholesterol levels were lower by 94.3, 91.0,
and 92.1 mg/dL (2.44, 2.36, and 2.39 mmol/L) for the CHA, PG, and MRFIT cohorts,
respectively (Table 2, Table 3, and Table 4). These lower serum cholesterol levels translate into estimated
greater life expectancy of 6.1, 8.7, and 3.8 years for the CHA, PG, and MRFIT
cohorts, respectively.
All Cancer Deaths. Cancer deaths numbered 225, 132, and 753 for the CHA, PG, and MRFIT
cohorts, respectively; there was no significant relation of baseline serum
cholesterol levels to cancer mortality (multivariate Cox coefficients, 0.0028, −0.0027,
and −0.0005; P>.10) (Table 5, Table 6, and Table 7).
All Violent Deaths. There were 130 (CHA cohort), 11 (PG cohort), and 414 (MRFIT cohort)
deaths from violent causes (injury, suicide, or homicide); no significant
association of serum cholesterol levels with risk of violent death was seen
(Cox multivariate coefficients, −0.0023, −0.0027, and 0.0020; P>.10) (Table 5, Table 6, and Table 7).
All Other Deaths. For the CHA and PG cohorts, there was no significant relation of serum
cholesterol level to risk of death from other causes (ie, non-CVD, noncancer,
nonviolent causes) (157 and 54 deaths, respectively; coefficients: −0.0012
and 0.0011, respectively; P>.10); for the MRFIT cohort,
with 412 such deaths, this association was inverse and statistically significant
(Cox multivariate coefficient, −0.0037; P<.01)
(Table 5, Table 6, and Table 7).
All Non-CVD Deaths. There was no significant relation of serum cholesterol level to all
non-CVD mortality (Cox multivariate coefficients, 0.0004, −0.0016, −0.0006; P>.10) (Table 5, Table 6, and Table 7). For men in the CHA and PG cohorts (aged 18-39 years and
25-39 years, respectively, at baseline), those with the lowest baseline serum
cholesterol levels (<160 mg/dL [<4.14 mmol/L]) generally had the lowest
mortality rate for each of the 4 listed non-CVD causes of death; for men in
the MRFIT cohort (aged 35-39 years at baseline), this subcohort had death
rates higher than for most other strata, significantly so only for other non-CVD
causes of death (Table 5, Table 6, and Table 7).
The main results of this study, consistent for these cohorts of younger
men, were first, there is a continuous, graded, strong, independent relationship
of serum cholesterol level to long-term risk of CHD and CVD death, stronger
than for men with like serum cholesterol levels measured in middle age; second,
with high serum cholesterol levels in young adulthood, there is substantial
absolute risk and absolute excess risk of CHD and CVD death over the decades
from young adulthood through middle age; third, there is almost no countervailing
evidence of any greater non-CVD mortality for younger adult men with favorable
serum cholesterol levels compared with others; fourth, consequently, for all
3 cohorts, there is a significant, positive, continuous graded relationship
of serum cholesterol level to long-term mortality from all causes; and finally,
substantially longer estimated life expectancy—3.8 to 8.7 years longer—is
observed for younger adult men with favorable serum cholesterol levels (<200
mg/dL [<5.17 mmol/L]) vs those with unfavorable levels (≥240 mg/dL [≥6.21
mmol/L]). Almost certainly, these strong relationships of serum cholesterol
level to long-term mortality are underestimates, because they are based on
only 1 cholesterol measurement per person, thus tending to produce misclassification
(regression dilution bias).20
These findings for younger men are in agreement with those for Johns
Hopkins medical students,6 (1017 men; average
age, 22 years) with serum cholesterol levels measured 1 to 11 times (median,
3) and averaged for analyses. During follow-up of the Hopkins cohort for 27
to 42 years (median, 30.5 years), serum cholesterol level was strongly related
to CHD and CVD incidence and mortality.6 After
adjustment for possible confounders, for serum cholesterol levels higher by
36 mg/dL (0.9 mmol/L) (75th vs 25th percentile), CHD and CVD RRs were 1.72
to 2.02. The non-CVD mortality rate was also higher across quartiles of serum
cholesterol levels, and risk of death before age 50 years was significantly
greater (RR, 1.64 with serum cholesterol levels higher by 36 mg/dL [0.9 mmol/L]).
Based on only 1 measurement, RRs were somewhat lower, eg, 1.50 for CVD incidence
(vs 1.72 with multiple measurements), reflecting regression dilution bias.6
For 597 men and 677 women aged 31 through 39 years at baseline in the
Framingham study, with 65 and 23 CVD deaths during 30 years of follow-up,7 findings are again similar to those of our study:
univariate Cox coefficient for the relationship of serum cholesterol to CVD
mortality 0.0096 for men and 0.0089 for women (RR with serum cholesterol higher
by 40 mg/dL [1.03 mmol/L], 1.47 and 1.43, respectively) (multivariate coefficients
not given). In the CHA study, of the 7676 women aged 18 through 39 years at
baseline (mean, 26.8 years), only 17 died from CHD during 25 years of follow-up,
too few to permit valid multivariate analyses of risk factor relations. In
Cox models like those for men, the coefficient for the serum cholesterol level–CHD
relationship was 0.0059 (t = 0.915),7
ie, qualitatively similar to the CHA men, the Framingham women, and the Johns
Hopkins and Framingham men.
All these data are consistent in showing high RRs of premature CHD and
CVD death for younger adults with high serum cholesterol levels vs those with
favorable levels. The CHA and Johns Hopkins findings further indicate that
for those with young adult hypercholesterolemia, both absolute risks and absolute
excess risks of CVD disease and death are high during the decades of middle
age, to age 65 years.
In sum, together with previously published findings, data from this
study provide powerful additional support to current public policy. First,
the results underline the strategic importance of population-wide primary
prevention of unfavorable serum cholesterol levels (and other major risk factors),
by improvement of lifestyles—particularly primary eating habits—from
conception and weaning on, so that a progressively higher proportion of adults
of all ages are at low risk.5,21,22
Second, they support population-wide efforts to identify children, teenagers,
and young adults—as well as others—with unfavorable serum cholesterol
levels (and other major risk factors), so that early therapeutic efforts can
be instituted, first and foremost, to improve nutrition.2,4,14,21,22
This second component of public policy is further buttressed by data from
autopsy studies showing the significant coronary atherosclerosis in young
American men and the relationship of serum lipids to such lesions.23,24
The feasibility of these objectives—and the fact that significant
progress has been made toward their achievement—is indicated by the
extensive data on population-wide reductions in intake of cholesterol, saturated
fat, and total fat over recent decades, and the concomitant declines in adult
prevalence rates of hypercholesterolemia and in population-wide average serum
cholesterol level from about 235 to 240 mg/dL (6.08-6.21 mmol/L) in the 1950s
to about 200 mg/dL (5.17 mmol/L) currently.5
The national health goal of an adult average serum cholesterol level no greater
than 200 mg/dL (5.17 mmol/L) has been achieved.22
The value of implementing these goals is supported by extensive data from
many randomized controlled trials. These data demonstrate efficacy for primary
and secondary (dietary and pharmacologic) interventions for CHD and CVD prevention
in achieving sustained reductions of unfavorable serum cholesterol levels.4,5,14 While there are no
such trials in young adults (such studies would need more than 20 years to
assess effects on "hard" clinical end points), it is a reasonable inference
that improved nutrition to reduce serum cholesterol levels is efficacious
for the whole population, including all young adults and particularly those
who already have unfavorable levels.
1.Stamler J. Lectures on Preventive Cardiology. New York, NY: Grune & Stratton; 1967.
2.Inter-Society Commission for Heart Disease Resources, Atherosclerosis
Study Group, and Epidemiology Study Group. Primary prevention of the atherosclerotic diseases.
Circulation.1970;42:A55-A95.Google Scholar 3.Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative
weight and ECG abnormalities to incidence of major coronary events: final
report of the Pooling Project.
J Chronic Dis.1978;31:201-306.Google Scholar 4. Summary of the second report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel II).
JAMA.1993;269:3015-3023.Google Scholar 5.Stamler J, Stamler R, Neaton JD.
et al. Low-risk factor profile and long-term cardiovascular and noncardiovascular
mortality and life expectancy: findings for 5 large cohorts of young adult
and middle-aged men and women.
JAMA.1999;282:2012-2018.Google Scholar 6.Klag MJ, Ford DE, Mead LA.
et al. Serum cholesterol in young men and subsequent cardiovascular disease.
N Engl J Med.1993;328:313-318.Google Scholar 7.Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham
study.
JAMA.1987;257:2176-2180.Google Scholar 8.Hulley SB, Walsh JM, Newman TB. Health policy on blood cholesterol: time to change directions.
Circulation.1992;86:1026-1029.Google Scholar 9.Stamler J, Stamler R, Brown WV.
et al. Serum cholesterol: doing the right thing.
Circulation.1993;88:1954-1960.Google Scholar 10.Stamler J, Stamler R, Brown WV.
et al. Reply to letters to editor on editorial, "Doing the right thing."
Circulation.1994;90:2573-2577.Google Scholar 12.Davidoff F. Evangelists and snails redux: the case of cholesterol screening.
Ann Intern Med.1996;124:513-514.Google Scholar 13.Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited.
Ann Intern Med.1996;124:518-531.Google Scholar 14.Cleeman JI, Grundy SM. National Cholesterol Education Program recommendations for cholesterol
testing in young adults: a science-based approach.
Circulation.1997;95:1646-1650.Google Scholar 15.Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R. Relationship of baseline major risk factors to coronary and all-cause
mortality, and to longevity: findings from long-term follow-up of Chicago
cohorts.
Cardiology.1993;82:191-222.Google Scholar 16.Levine JB, Zak B. Automated determination of serum cholesterol.
Clin Chim Acta.1964;10:381-384.Google Scholar 17.Prineas RJ, Castle CH, Curb JD, Harrist R, Lewin A, Stamler J. Hypertension Detection and Follow-up Program: baseline electrocardiographic
characteristics of the hypertensive participants.
Hypertension.1983;5(6 pt 2):160-189.Google Scholar 18.Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum
and demonstration of its specificity.
J Biol Chem.1952;195:357-366.Google Scholar 19.National Center for Health Statistics. Vital Statistics of the United States, 1990. Vol 2. Washington, DC: Public Health Service; 1994:12.
20.MacMahon S, Peto R, Cutler J.
et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences
in blood pressure: prospective observational studies corrected for the regression
dilution bias.
Lancet.1990;335:765-774.Google Scholar 21.Deckelbaum RJ, Fisher EA, Winston M.
et al. Summary of a scientific conference on preventive nutrition: pediatrics
to geriatrics.
Circulation.1999;100:450-456.Google Scholar 22.National Heart, Lung, and Blood Institute. Cardiovascular health for all: NHLBI sets new heart agenda.
Heart Memo.Summer 1999:1-5.Google Scholar 23.Berenson GS, Srinivasan SR, Bao W, Newman III WP, Tracy RE, Wattigney WA.for the Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis
in children and young adults.
N Engl J Med.1998;338:1650-1656.Google Scholar 24.Mahoney LT, Burns TL, Sanford W.
et al. Coronary risk factors measured in childhood and young adult life are
associated with coronary artery calcification in young adults: the Muscatine
Study.
J Am Coll Cardiol.1996;27:277-284.Google Scholar